ArticlePreventive medicine reports2026
Hyperlipidemia and associated risk factors among people living with HIV on antiretroviral therapy: a retrospective cohort study from Eastern China.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the incidence of hyperlipidemia and identify its associated risk factors among people living with HIV (PLWH) initiating antiretroviral therapy (ART) in Eastern China, with the aim of informing strategies for early identification and timely management. Methods: We conducted a retrospective cohort study of PLWH who initiated antiretroviral therapy (ART) in Zhejiang Province from January 2019 to December 2021. Demographic characteristics, clinical details, and other relevant factors were retrieved from the National Free ART Database. Results: A total of 4387 PLWH were observed, with an incidence of hyperlipidemia of 43.8/100 person-years. A higher baseline CD4 cell count was associated with a reduced risk of hyperlipidemia: 51-200 cells/μL (aHR 0.75, 95% CI 0.65,0.87), 201-500 cells/μL (aHR 0.67, 95% CI 0.58,0.78), 501+ cells/μL (aHR 0.70, 95%CI 0.58, 0.84). Zidovudine + lamivudine + efavirenz, tenofovir disoproxil fumarate + lamivudine + lopinavir/ritonavir, elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide had a higher risk of hyperlipidemia. An HIV load ≥1000 copies/mL (aHR 4.03, 95% CI 3.67,4.42) was linked to an increased risk of hyperlipidemia. Conclusions: A high incidence of hyperlipidemia was observed in PLWH receiving ART. Strengthening blood lipid monitoring and managing modifiable risk factors are essential to prevent hyperlipidemia in PLWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.